Bartonella quintana lipopolysaccharide (LPS): Structure and characteristics of a potent TLR4 antagonist for in-vitro and in-vivo applications

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Malgorzata Miller, Gosia ^a,b   Heinbockel, Lena ^c   Brandenburg, Klaus ^c   Van Der Meer, Jos W M ^a   Netea, Mihai G ^a,b   Joosten, Leo A B ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84989172762     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34221     Document Type: Article

References (57)

1. Miller, S. I, Ernst, R. K. & Bader, M. W. LPS, TLR4 and infectious disease diversity. Nat. Rev. Microbiol. 3, 36-46 (2005).
2. Fitzgerald, K. A, Rowe, D. C. & Golenbock, D. T. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect. 6, 1361-1367 (2004).
3. Kaisho, T. & Akira, S. Critical roles of Toll-like receptors in host defense. Crit. Rev. Immunol. 20, 393-405 (2000).
4. Pal, D. et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance Nat. Med. 18, 1279-1285 (2012).
5. Shi, B. et al. SNAPIN: an endogenous Toll-like receptor ligand in rheumatoid arthritis. Ann. Rheum. Dis. 71, 1411-1417 (2012).
6. Abdollahi-Roodsaz, S, Joosten, L. A, Koenders, M. I, van den Brand, B. T, van de Loo, F. A. & van den Berg, W. B. Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4. activation. Am. J. Pathol. 175, 2004-2013 (2009).
7. Wu, H. et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J. Clin. Invest. 117, 2847-2859 (2007).
8. Vogl, T. et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13, 1042-1049 (2007).
9. Goh, F. G, Piccinini, A. M, Krausgruber, T, Udalova, I. A. & Midwood, K. S. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J. Immunol. 184, 2655-2662 (2010).
10. Stifano, G. et al. Chronic Toll-like receptor 4. stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis. Arthritis Res. Ther. 16, R136 (2014).
11. Jia, L. et al. Hepatocyte Toll-like receptor 4. regulates obesity-induced inflammation and insulin resistance. Nat. Commun. 5, 3878-3885 (2014).
12. Liu, Y, Yin, H, Zhao, M. & Lu, Q. TLR2 and TLR4 in Autoimmune Diseases: Comprehensive Review. Clin. Rev. Allergy Immunol. 47, 136-147 (2014).
13. Den Dekker, W. K, Cheng, C, Pasterkamp, G. & Duckers, H. J. Toll like receptor 4. in atherosclerosis and plaque destabilization. Atherosclerosis 209, 314-320 (2010).
14. Kim, J. K. Fat uses a TOLL-road to connect inflammation and diabetes. Cell Metab 4, 417-419 (2006).
15. Abdollahi-Roodsaz, S. et al. Inhibition of Toll-like receptor 4. breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum. 56, 2957-2967 (2007).
16. Foucault, C, Barrau, K, Brouqui, P. & Raoult, D. Bartonella quintana Bacteremia among Homeless People. Clinical Infect. Dis. 35, 684-689 (2002).
17. Foucault, C, Brouqui, P. & Raoult, D. Bartonella quintana characteristics and clinical management. Emerg. Infect. Dis. 12, 217-223 (2006).
18. Angelakis, E. & Raoult, D. Pathogenicity and treatment of Bartonella infections. Int J Antimicrob Agents 44, 16-25 (2014).
19. Liberto, M. C, Matera, G, Lamberti, A. G, Barreca, G. S, Quirino, A. & Foca, A. In vitro Bartonella quintana infection modulates the programmed cell death and inflammatory reaction of endothelial cells. Diagnostic Microbiol. Infect. Dis. 45, 107-115 (2003).
20. Matera, G. et al. The Janus face of Bartonella quintana recognition by Toll-like receptors (TLRs): a review. Eur. Cytokine Netw. 19, 113-118 (2008).
21. Pulliainen, A. T. & Dehio, C. Persistence of Bartonella spp. stealth pathogens: from subclinical infections to vasoproliferative tumor formation. FEMS Microbiology Reviews 36, 563-599 (2012).
22. Capo, C, Amirayan-Chevillard, N, Brouqui, P, Raoult, D. & Mege, J. L. Bartonella quintana bacteremia and overproduction of interleukin-10: model of bacterial persistence in homeless people. J. Infect. Dis. 187, 837-844 (2003).
23. Popa, C. et al. Bartonella quintana lipopolysaccharide is a natural antagonist of Toll-like receptor 4. Infect. Immun. 75, 4831-4837 (2007).
24. Den Dekker, W. K. et al. Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4. activation pathway. Arterioscler. Thromb. Vasc. Biol. 32, 1960-1969 (2012).
25. Vaneker, M. et al. Low-tidal-volume mechanical ventilation induces a toll-like receptor 4-dependent inflammatory response in healthy mice. Anesthesiology 109, 465-472 (2008).
26. Drali, R. et al. Bartonella quintana in body lice from scalp hair of homeless persons, France. Emerg. Infect. Dis. 20, 907-908 (2014).
27. Matera, G. et al. Bartonella quintana lipopolysaccharide effects on leukocytes, CXC chemokines and apoptosis: a study on the human whole blood and a rat model. Int. Immunopharmacol. 3, 853-864 (2003).
28. Mueller, M, Brandenburg, K, Dedrick, R, Schromm, A. B. & Seydel, U. Phospholipids inhibit lipopolysaccharide (LPS)-induced cell activation: a role for LPS-binding protein. J. Immunol. 174, 1091-1096 (2005).
29. van den Plas, M. L. et al. Rhizobium sin-1 lipopolysaccharide (LPS) prevents enteric LPS-induced cytokine production. J. Biol. Chem. 277, 41811-41816 (2002).
30. Komaniecka, I, Choma, A, Lindner, B. & Holst, O. The structure of a novel neutral lipid A from the lipopolysaccharide of Bradyrhizobium elkanii containing three mannose units in the backbone. Chemistry 16, 2922-2929 (2010).
31. Brandenburg, K, Andrä, J, Müller, M, Koch, M. H. & Garidel, P. Physicochemical properties of bacterial glycopolymers in relation to bioactivity. Carbohydr. Res. 338, 2477-2489 (2003).
32. Schromm, A. B. et al. Physicochemical and biological analysis of synthetic bacterial lipopeptides: validity of the concept of endotoxic conformation. J. Biol. Chem. 282, 11030-11037 (2007).
33. Seydel, U, Koch, M. H. J. & Brandenburg, K. Structural polymorphisms of rough mutant lipopolysaccharides Rd to Ra from Salmonella minnesota. J Struct Biol. 110, 232-243 (1993).
34. Peri, F. & Piazza, M. Therapeutic targeting of innate immunity with Toll-like receptor 4. (TLR4) antagonists. Biotechnol. Adv. 30, 251-260 (2012).
35. Mullarkey, M, Rose, J, Bristol, J, Kawata, T, Kimura, A. & Kobayashi, S. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4. directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304, 1093-1102 (2003).
36. Brandenburg, K. & Wiese, A. Endotoxins:Relationship between structure, function, and activity. Curr. Top. Medicin. Chem. 4, 1127-1146 (2004).
37. Švajger, U. et al. Novel toll-like receptor 4. (TLR4) antagonists identified by structure- and ligand-based virtual screening. Eur. J. Med. Chem. 70, 393-399 (2013).
38. Brandenburg, K, David, A, Howe, J, Koch, M. H, Andrä, J. & Garidel, P. Temperature dependence of the binding of endotoxins to the polycationic peptides polymyxin B and its nonapeptide. Biophys. J. 88, 1845-18458 (2005).
39. Macagno, A. et al. A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. J. Exp. Med. 203, 1481-1492 (2006).
40. Belcher, J. D. et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 123, 377-390 (2014).
41. Zhang, X. et al. Toll-like receptor 4. plays a central role in cardiac dysfunction during trauma hemorrhage shock. Shock 42, 31-37 (2014).
42. Shirey, K. A. et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497, 498-502 (2013).
43. Shang, L. et al. Selective Antibody Intervention of Toll-like Receptor 4. Activation through Fc γ Receptor Tethering. J. Biol. Chem. 289, 15309-15318 (2014).
44. Andersson, U. & Tracey, K. J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29, 139-162 (2011).
45. Ehrchen, J. M, Sunderkötter, C, Foell, D, Vogl, T. & Roth, J. The endogenous Toll-like receptor 4. agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J. Leukoc. Biol. 86, 557-566 (2009).
46. Schelbergen, R. F. et al. Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum. 64, 1477-1487 (2012).
47. Bhattacharyya, S. et al. Fibronectin EDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med. 6, 232ra50 (2014).
48. Abdollahi-Roodsaz, S. et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J. Clin. Invest. 118, 205-216 (2008).
49. Morrison, D. C. & Leive, L. Isolation and characterization of two fractions of lipopolysaccharide from E. coli 0111:B4. J. Biol. Chem. 250, 2911-2919 (1975).
50. Mylona, E. E. et al. Enhanced interleukin-1β production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. Arthritis Res. Ther. 14, R158 (2012).
51. Oosting, M. et al. Role of interleukin-23 (IL-23) receptor signaling for IL-17 responses in human Lyme disease. Infect. Immun. 79, 4681-4687 (2011).
52. Buffen, K. et al. Autophagy modulates Borrelia burgdorferi-induced production of interleukin-1β (IL-1β ). J. Biol. Chem. 288, 8658-8666 (2013).
53. Kleinnijenhuis, J. et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl. Acad. Sci. USA 109, 17537-17542 (2012).
54. Weber, M. A. et al. Endogenous leukemia inhibitory factor attenuates endotoxin response. Lab. Invest. 85, 276-284 (2005).
55. Zehethofer, N. et al. Lipid Analysis of Airway Epithelial Cells for Studying Respiratory Diseases. Chromatographia 78, 403-413 (2015).
56. Roessle, M. et al. Upgrade of the small-angle X-ray scattering beamline at the European Molecular Biology Laboratory, Hamburg. J. Appl. Crystallogr. 40, 190-194 (2007).
57. Zähringer, U. et al. Structure and biological activity of the short-chain lipopolysaccharide from Bartonella henselae ATCC 49882T. J Biol Chem. 279, 21046-21054 (2004).